Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRX002-02 repeated-dose intrapleural therapy in malignant pleural mesothelioma
jRCT2061220015Phase 1Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2022
- Modality
- miRNA Mimics → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, miRNA Inhibitors → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MIRX002 in pleural mesothelioma, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Primary safety and tolerability endpoint. Started Apr 2022; status: completed.
02
Drugs
MIRX002
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on jRCT2061220015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220015.